Clinical trial

Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small…

NCT00003281 · Alliance for Clinical Trials in Oncology, Other · Completed

Key facts

NCT number NCT00003281
Title Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
Official title Phase II Trial of Topotecan and Paclitaxel in Previously Treated Patients With Relapsed Small Cell Lung Cancer
Lead sponsor Alliance for Clinical Trials in Oncology, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Lung Cancer
Intervention type Drug, Radiation
Interventions paclitaxel, topotecan hydrochloride, radiation therapy
Enrollment 84
Start date Apr 1, 1998
Primary completion Mar 1, 2006
Completion Mar 1, 2006
First posted Sep 24, 2003
Last update posted Jul 13, 2016
Countries Canada, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies